Treat to target in systemic lupus erythematosus: a commentary

Manuel F. Ugarte-Gil, Paula I. Burgos, Graciela S. Alarcón

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

6 Citas (Scopus)


Treat to target (T2T) strategies have proved to be useful in several chronic disorders, including Rheumatoid Arthritis. In systemic lupus erythematosus (SLE), T2T strategy has been proposed in order to control disease activity, improve health-related quality of life, and reduce morbidity and mortality. Remission would be the main target, but a low disease activity state (LDAS) could be an acceptable alternative. However, due to SLE protean manifestations, the operational definitions of both remission and LDAS are still in progress. The definitions of these targets, remission and LDAS, should include a validated disease activity index, the treatments allowed, and the minimum length of time the target should be maintained. Furthermore, achieving these targets should result in better disease outcomes such as reducing damage accrual. This review addresses the current state regarding these possible targets in SLE and the impact of achieving them in intermediate and long-term outcomes of this disease.

Idioma originalInglés
Páginas (desde-hasta)1903-1907
Número de páginas5
PublicaciónClinical Rheumatology
EstadoPublicada - 1 ago. 2016


Profundice en los temas de investigación de 'Treat to target in systemic lupus erythematosus: a commentary'. En conjunto forman una huella única.

Citar esto